The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MYNZ | -83.87% | N/A | N/A | -100% |
| S&P | +18.54% | +92.9% | +14.04% | +44% |
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.
| Q4 2023 | YOY Change | |
|---|---|---|
| Revenue | $0.21M | 0.0% |
| Gross Profit | -$0.10M | 0.0% |
| Gross Margin | -48.84% | 0.0% |
| Market Cap | $19.43M | 0.0% |
| Net Income | -$5.18M | 0.0% |
| EBITDA | -$6.35M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2023 | YOY Change | |
|---|---|---|
| Net Cash | $7.07M | 0.0% |
| Accounts Receivable | $0.09M | 0.0% |
| Inventory | 0.6 | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.17M | 0.0% |
| Short Term Debt | $5.19M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -105.78% | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.82M | 0.0% |
| Operating Free Cash Flow | -$4.66M | 0.0% |
| Metric | Q4 2023 | YoY Change |
|---|---|---|
| Price to Book | 5.63 | - |
| Price to Sales | 27.42 | - |
| Price to Tangible Book Value | -8960.71 | - |
| Enterprise Value to EBITDA | -3.75 | - |
| Total Debt | $6.36M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
